Range Capital Acquisition II, a blank check company targeting capital-constrained sectors, raised $200 million by offering 20 million units at $10.00. Each unit consists of one share of common stock and one-half of one warrant exercisable at $11.50.
The company is being led by CEO Tim Rotolo, who founded and currently serves as CEO of Lloyd Harbor Capital Management, and CFO Andrew Kucharchuk, who currently serves as CFO of Cero Therapeutics (Nasdaq: CERO) and Theralink Technologies (OTC: THER). The SPAC plans to target undervalued assets in capital constrained markets, including niche markets.
Management's previous SPAC, Range Capital Acquisition (RANGU), went public in December 2024 and is still searching for a target.
Range Capital Acquisition II plans to list on the Nasdaq under the symbol RNGTU. BTIG acted as sole bookrunner on the deal.
